| Geld/Brief | 23,06 $ / 25,00 $ |
| Spread | +8,41% |
| Schluss Vortag | 24,87 $ |
| Gehandelte Stücke | 677.203 |
| Tagesvolumen Vortag | 1.297.475 $ |
| Tagestief 22,96 $ Tageshoch 23,29 $ | |
| 52W-Tief 19,05 $ 52W-Hoch 26,58 $ | |
| Jahrestief 22,13 $ Jahreshoch 25,53 $ | |
| Umsatz in Mio. | 491,73 $ |
| Operatives Ergebnis (EBIT) in Mio. | 195,12 $ |
| Jahresüberschuss in Mio. | 163,89 $ |
| Umsatz je Aktie | 3,89 $ |
| Gewinn je Aktie | 1,30 $ |
| Gewinnrendite | +22,52% |
| Umsatzrendite | +33,33% |
| Return on Investment | +19,25% |
| Marktkapitalisierung in Mio. | 2.635 $ |
| KGV (Kurs/Gewinn) | 16,05 |
| KBV (Kurs/Buchwert) | 3,62 |
| KUV (Kurs/Umsatz) | 5,37 |
| Eigenkapitalrendite | +22,52% |
| Eigenkapitalquote | +85,46% |
| Faktor-Zertifikate | 6 | |
| Knock-Outs | 3 |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 20,82 € | +0,73% | 20,67 € | 27.02.26 | |
| Frankfurt | 21,11 € | +3,28% | 20,44 € | 27.02.26 | |
| Hamburg | 20,96 € | 0 % | 20,96 € | 27.02.26 | |
| München | 20,84 € | 0 % | 20,84 € | 27.02.26 | |
| Stuttgart | 19,425 € | -7,89% | 21,09 € | 27.02.26 | |
| L&S RT | 19,52 € | 0 % | 19,52 € | 13:04 | |
| NYSE | 23,00 $ | -7,48% | 24,86 $ | 27.02.26 | |
| Nasdaq | 23,075 $ | -7,22% | 24,87 $ | 27.02.26 | |
| AMEX | 23,23 $ | -6,97% | 24,97 $ | 27.02.26 | |
| Tradegate | 19,425 € | -7,81% | 21,07 € | 27.02.26 | |
| Quotrix | 21,00 € | +0,24% | 20,95 € | 27.02.26 | |
| Gettex | 19,50 € | -7,41% | 21,06 € | 27.02.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 27.02.26 | 23,07 | 1,50 M |
| 26.02.26 | 24,87 | 1,34 M |
| 25.02.26 | 24,84 | 1,22 M |
| 24.02.26 | 24,19 | 0,97 M |
| 23.02.26 | 24,11 | 1,17 M |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 24,30 $ | -5,04% |
| 1 Monat | 24,07 $ | -4,13% |
| 6 Monate | 20,19 $ | +14,29% |
| 1 Jahr | 21,66 $ | +6,53% |
| 5 Jahre | 3,89 $ | +493,19% |
| Marktkapitalisierung | 3,69 Mrd. € |
| Aktienanzahl | 178,41 Mio. |
| Streubesitz | 6,81% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +15,44% | BlackRock Inc |
| +7,16% | Vanguard Group Inc |
| +4,48% | State Street Corp |
| +2,66% | Renaissance Technologies Corp |
| +2,60% | Morgan Stanley - Brokerage Accounts |
| +2,35% | Deerfield Management Co |
| +2,34% | Geode Capital Management, LLC |
| +2,21% | Fundsmith LLP |
| +1,97% | Goldman Sachs Group Inc |
| +1,93% | Bank of America Corp |
| +1,56% | Dimensional Fund Advisors, Inc. |
| +1,44% | American Century Companies Inc |
| +1,29% | Royce & Associates, LP |
| +1,17% | Charles Schwab Investment Management Inc |
| +1,05% | Boston Partners Global Investors, Inc |
| +1,04% | Northern Trust Corp |
| +1,00% | Arrowstreet Capital Limited Partnership |
| +0,99% | Amvescap Plc. |
| +0,85% | Allianz Asset Management AG |
| +0,83% | Qube Research & Technologies |
| +38,82% | Weitere |
| +6,81% | Streubesitz |
Zahlen für Q3/20
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-third-quarter-2020-financial
Bundesrichter entscheidet im Sinne der FDA & Jacobus Pharmaceuticals
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-ruling-lawsuit-against-fda
Catalyst Pharma hat die Klage gegen die FDA verloren
Das könnte Ruzurgi(Amifampridin) von Jacobus Pharmaceutical bei Erwachsenen LEMS-Patienten den Weg ebnen.
https://seekingalpha.com/news/3598477-catalyst-pharma-down-13-on-adverse-ruling-in-fda-lawsuit
MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-second-quarter-2020-financial
Zahlen für Q2/20
